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Abstract
Photodynamic therapy (PDT) is a light-based treatment modality in which wavelength specific
activation of a photosensitizer (PS) generates cytotoxic response in the irradiated region.
PDT response is critically dependent on several parameters including light dose, PS dose,
uptake time, fluence rate, and the mode of light delivery. While the systematic optimization of
these treatment parameters can be complex, it also provides multiple avenues for enhancement of PDT efficacy under diverse treatment conditions, provided that a rational
framework is established to quantify the impact of parameter selection upon treatment response. Here we present a theranostic technique, combining the inherent ability of the PS to
serve simultaneously as a therapeutic and imaging agent, with the use of image-based
treatment assessment in three dimensional (3D) in vitro tumor models, to comprise a platform
to evaluate the impact of PDT parameters on treatment outcomes. We use this approach to
visualize and quantify the uptake, localization, and photobleaching of the PS benzoporphyrin
derivative monoacid ring-A (BPD) in a range of treatment conditions with varying uptake
times as well as continuous and fractionated light delivery regimens in 3D cultures of AsPC-1
and PANC-1 cells. Informed by photobleaching patterns and correlation with cytotoxic response, asymmetric fractionated light delivery at 4 hours BPD uptake was found to be the
most effective regimen assessed. Quantification of the spatial profile of cell killing within
multicellular nodules revealed that these conditions also achieve the highest depth of cytotoxicity along the radial axis of 3D nodules. The framework introduced here provides a means
for systematic assessment of PDT treatment parameters in biologically relevant 3D tumor
models with potential for broader application to other systems.
Key words: Photodynamic therapy, PDT, photosensitizer imaging, fractionation, verteporfin, BPD,
in vitro 3D tumor model.

Introduction
Photodynamic therapy (PDT) is an emerging
anticancer treatment [1-5] that uses a light-activated
chemical, or photosensitizer (PS) which localizes
somewhat preferentially in neoplastic tissue and induces a cytotoxic response upon activation by the

appropriate wavelength of light [6]. The cytotoxic
response generated by PDT can be enhanced by adjusting a panoply of parameters which include light
dose, photosensitizer dose, uptake time, irradiance,
and light delivery modulation. This large set of therhttp://www.thno.org
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apeutic parameters simultaneously elevates the complexity of the treatment and provides multiple avenues for customization and optimization. Importantly, most PDT agents are intrinsically theranostic as
they are useful both for therapeutic and for diagnostic
purposes. This is because the photosensitizing species
used for PDT, in addition to generating cytotoxicity,
also almost universally have a finite quantum yield
for fluorescence emission, providing a powerful intrinsic capability for monitoring of uptake, localization, and photobleaching, which can in turn be utilized to inform these critical variables in treatment
design. In addition, the fluorescence can be used for
diagnostic applications such as image-guided resection [6, 7]. Here, we present a methodology which
combines the unique ability of the PS to serve simultaneously as an imaging agent and a light-activated
therapeutic; with 3D tumor models that restore
physiologically-relevant tumor architecture and are
conducive to interrogation by optical imaging.
Building on the previous development of
high-content image processing for therapeutic assessment in 3D cancer models [8, 9], we integrate a
new set of analyses for in situ quantification of photosensitizer uptake, localization, and photobleaching
to comprise a new theranostic approach for spatio-temporal correlation of PDT parameters and
treatment effects across populations of individual in
vitro 3D tumor micronodules that resemble multifocal
nodular studding in vivo. We further demonstrate the
ability of this integrative platform to inform the optimization PDT parameters.
Optimization of dosimetry in PDT is a complex
process that is usually system specific and depends on
many parameters that are closely interrelated. Such
parameters include light dose, light fluence rate, concentration of photosensitizer administered, and photosensitizer uptake time [10, 11]. To address the difficulties that dosimetry presents, many prior studies
have focused on quantification of photosensitizer
photobleaching as an indicator of treatment efficacy
[12-14]. Others studies have involved imaging photosensitizer localization and uptake [15, 16] while
fewer have attempted to monitor singlet oxygen generation and/or triplet oxygen depletion to determine
optimal irradiation times [17, 18]. Singlet oxygen detection is arguably the most direct way of predicting
treatment efficacy in oxygen-dependent PDT and thus
optimizing treatment regimens, but it is very difficult
to accurately measure in practice. Photobleaching,
while less direct, generally correlates well with cytotoxic response, is affected by nearly all of the adjustable parameters (e.g., light dose, irradiance, photosensitizer dose, etc.), and is far easier to quantify and, in
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some cases, visualize.
Another adjustable parameter, the determination
of which can be aided by our technique, is modulation
of light delivery. An extensively studied [18-20] adjustment is the fractionation of delivered light, which
involves irradiating with interspersed rest periods in
which no light is administered until a total fluence is
achieved (e.g., a 33s on/33s off/33s on schedule to
achieve a 10 J/cm2 light dose at 150 mW/cm2).
Though the benefit from fractionated irradiation observed, if any, is highly dependent on the system
studied (e.g., photosensitizer used, oxygenation conditions, etc.) [21-23], it has been suggested that the
effect is mainly due to reoxygenation of hypoxic tumor regions [24, 25]. Increased PPIX production during the dark intervals of fractionated ALA-PDT has
also been suggested [26]. Consequently, any enhancement in cytotoxic response would be expected
to correlate with photobleaching patterns. Therefore,
fractionation regimens can be chosen based on informed analyses from our imaging-based technique.
To demonstrate this utility, we pursued asymmetric
in addition to symmetric fractionation regimens on
the seconds scale as we hypothesized shorter irradiation intervals would result in less photobleaching
while longer dark intervals would allow greater reoxygenation, a methodology somewhat similar to
radiotherapy treatments. Asymmetric fractionation
regimens would consist of 33s on/66s off, 33s on/99s
off, et cetera, irradiation schemes.
In this study, we explore each of the PDT parameters mentioned above in a three-dimensional
cancer model. As a result of the current interest in
PDT as a potential treatment for pancreatic ductal
adenocarcinoma [27], we have elected to use the pancreatic cancer cell lines AsPC-1 and PANC-1 for the
development and demonstration of our imaging-based method. Three-dimensional in vitro cell
culture models have, in recent years, been developed
into more physiologically relevant and more reliable
reporters of treatment response than conventional
monolayer cultures [9]. Here we employ a 3D culture
overlay geometry adapted from a system previously
characterized using ovarian cancer lines that is conducive to high-content imaging [8, 9, 28]. In addition
to the new imaging approaches introduced here, we
also utilize previously described [8, 9, 27, 29] imaging-based techniques to quantify cytotoxic response in
large fields consisting of thousands of nodules. The
capabilities of the imaging-based method to be presented will thus be leveraged to visualize and quantify the results of PDT parameter adjustment by monitoring uptake, localization, and photobleaching patterns.
http://www.thno.org
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Methods and Materials
Cell Lines and Reagents
AsPC-1 and PANC-1 cell lines were obtained
from American Type Culture Collection (ATCC,
Rockville, MD) and grown according to ATCC descriptions. Cell media and fetal bovine serum were
obtained from Mediatech (Herndon, VA) and Invitrogen (Carlsbad, CA), respectively. To all cell media
was added 50 IU/mL penicillin and 50 mg/mL
streptomycin (Mediatech). PDT treatments were
conducted using the photosensitizer benzoporphyrin
derivative monoacid ring-A (BPD, common name
Verteporfin, VWR, Radnor, PA). Quoted concentrations of BPD were confirmed using its UV-VIS absorbance spectrum and previously characterized
photophysical properties [30].

Growth of 3D Tumor Nodules on Basement
Membrane
Cells were grown in overlay on a bed of Growth
Factor Reduced (GFR) Matrigel™ (BD Biosciences,
Bedford, MA) as a basement membrane to mimic
stromal interactions in pancreatic cancer, as previously described [8, 27, 31]. In this work, 250 μL of
Matrigel was deposited into each well of a 24-well
plate so that beds several hundred microns in thickness completely covered the well bottoms. As cells
were plated in overlay and not embedded in the matrix, any variations in the bed thickness will not affect
growth and/or treatment outcomes. Cells were
grown for 10 to 12 days prior to initiation of treatment
and/or imaging of BPD uptake. Media changes with
2% GFR Matrigel-supplemented media were performed once every third day during the growth process. To illustrate the three-dimensional structure of
the nodules, comprehensive Z-stack images of
cleaved Calcein and Propidium Iodide fluorescence,
which label viable and dead cells, respectively, were
taken on the Olympus FV-1000 confocal at 40X for
treated and untreated day 12 AsPC-1 nodules. Images
acquired at representative Z-positions as well as 3D
renderings of each Z-stack are presented in Additional File 1: Supplemental Figure 1. At the time of imaging and PDT treatment, the 3D cultures for both cell
lines had adopted a highly reproducible bimodal
Gaussian distribution of nodule sizes (see Additional
File 1: Supplemental Figure 2).

Imaging of Verteporfin (BPD) Uptake and
Localization
On the day of imaging, cells were incubated
with 1 μM BPD in cell media for various time intervals
quoted in the text. BPD media was then replaced with
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BPD-free media. To quantify verteporfin uptake and
localization within tumor nodules, an imaging-based
method was developed for the three-dimensional
model to quantify uptake and localization of BPD
using fluorescence imaging. Images were obtained
using an Olympus FV-1000 confocal microscope. The
photosensitizer was excited with the 488 nm line from
an Argon ion laser. Optimal dichroic mirror, filter,
and detector settings for the fluorescence channel
were established by imaging BPD, the spectrum of
which was verified in hyperspectral scans. For all BPD
fluorescence images, an objective magnification of 4X
(NA = 0.16) was used to collect single-images that
were digitally zoomed by a factor of 1.4. Each imaged
area was 2.3 mm x 2.3 mm in size and consisted of
approximately one hundred nodules. Individual
treatment groups were performed in triplicate, yielding statistics across hundreds of nodules. While a
confocal microscope was used for image acquisition,
the confocality of the instrument was not necessary
for our technique: the confocal pinhole diameter was
opened to 600 μm to collect the maximal amount of
fluorescence signal. With this aperture size, the
in-plane resolution and optical section thickness were
estimated to be 1.5 μm and 310 μm, respectively. Individual image fields were saved for offline processing using routines that we developed in
MATLAB.
The analysis routine first calculates mean pixel
intensities of each individual fluorescence image. The
average fluorescence intensities from the no treatment
groups are then assumed to be background and subtracted from the mean fluorescence intensities of
groups which received photosensitizer. The background subtracted fluorescence intensities are then
used as a metric for reporting the relative mean concentration of photosensitizer in the nodules. In addition, individual matrix elements of post-treatment
images are subtracted from each pre-treatment image
element to generate photobleaching maps.

Quantification of Verteporfin (BPD) Photobleaching
Photobleaching effects were visualized by imaging each well of the plates pre- and post- PDT
treatment. Identical imaged areas were acquired directly before and after PDT treatment and during
evaluation of cytotoxic response. Using the aforementioned MATLAB routines, mean fluorescence
intensity of the pre- and post- treatment images was
calculated and the mean residual BPD in each group
reported as the ratio of the residual BPD of each
treatment group to that of the BPD only control.
Photobleaching maps were also generated by subhttp://www.thno.org
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tracting each element of the post-treatment image
matrix from each element of the pre-treatment’s image and visualized with the “hot” color map in
MATLAB. Pixel intensity line scans of individual
nodules from raw fluorescence images were performed using the public domain image analysis software ImageJ [32].

PDT Treatments
Cell cultures were incubated with medium containing 1 μM BPD for time intervals of 1.5, 4, and 24
hours. Prior to irradiation, the medium was replaced
with BPD-free medium. Cells were irradiated at specified doses using a 690 nm laser diode source (Model
7401; Intense, North Brunswick, NJ) at a fluence rate
of 150 mW/cm2 as measured via a VEGA laser power
energy meter (Ophir Laser Measurement Group, LLC)
and then allowed to incubate for 24 hours prior to
evaluation of treatment response. Laser irradiation
was delivered through the bottom of each well on a
clear plastic tray via a vertically mounted Thorlabs
FT600EMT multimode fiber (Thorlabs, Newton, NJ),
which was collimated to overfill the dish area for
nearly uniform light delivery.
A robust system that integrates an electronic TTL
logic shutter and computer code was used to provide
highly reproducible light doses. The irradiation times
corresponding to specified light doses were calculated
to the nearest hundredth of a second using a custom
routine written in C and compiled in Igor Pro
(Wavemetrics, Lake Oswego, OR). The program also
runs a USB-6210 counter/timer board (National Instruments), which creates +5V TTL pulse trains to
operate an Ocean Optics INLINE-TTL-S fiber-coupled
shutter (Ocean Optics, Dunedin, FL) to deliver light
consistently for the calculated irradiation interval. For
continuous irradiation treatments, the pulse train
from the counter/timer board consisted of one pulse
in HIGH logic (+5V, open shutter) for the duration of
the treatment. For fractionated light delivery, irradiation periods correspond to the time in which the pulse
train is in HIGH logic, while LOW logic (-5V, closed
shutter) corresponds to dark intervals. Fractionation
regimens were determined by splitting the counterpart continuous light dose in half (i.e., only one rest
period), beginning with symmetric fractionation (e.g.,
33s on/33s off) and then increasing the asymmetry of
the light/dark interval (e.g., 33s on/66s off, etc.). A
fluence of 10 J/cm2 is therefore accomplished by irradiating in a 33s on/33s off/33s on fractionation
schedule.

Cell Viability Measurements
Viability of treated cultures was assessed using a
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previously described [8, 9] imaging-based technique
to quantify cells positively stained with Calcein AM
(Invitrogen) as a fluorescent label for viable cells and
Propidium Iodide (Sigma Aldrich) as a marker for
dead cells. All wells were incubated with Calcein AM
and Propidium Iodide reagents for 40 minutes prior to
imaging on an Olympus FV-1000 confocal microscope
using a 0.16NA 4X objective to obtain single-image
fields 2.3 mm x 2.3 mm in size consisting of many
nodules. The 488 nm line from an Argon ion laser
with paired with a FITC filter set and a 559 nm diode
source paired with a TRITC filter set was used to detect cleaved Calcein and intercalated Propidium, labeling viable and dead cells respectively. Saved images were batch-processed in MATLAB using a routine to segment the fluorescence images, determine
mean pixel intensities for the Calcein (live) and Propidium Iodide (dead) channels separately, and subsequently calculate viability from the mean intensities
using the formula live/(live+dead) as previously described [8] and also using a complete killing control
(fixed and permeablized cultures) to standardize the
dynamic range of fluorescence intensity from the two
channels [29]. Fractional viability was reported as the
ratio of the viability of a given treatment group to that
of the no treatment control group for identical plating
conditions and growth period. Validation of this imaging-based approach to quantifying treatment response in the 3D model against common colorimetric
assays is not straightforward as assay reagents (e.g.,
MTT) bind to the Matrigel substrate. However, the
method has been used previously in monolayer cell
cultures [9] and provided comparable viabilities to
that obtained via the MTT assay (see Additional File 1:
Supplemental Figure 3).

Results
Overview of PDT Treatment Parameters and
the Imaging-Based Method
Figure 1 gives an overview of the parameters
involved in a given PDT treatment as well as the capabilities of our imaging-based technique. PS fluorescence images are displayed based on a 12-bit colormap to easily identify areas of high pixel intensity.
As expected, the No Treatment group contains no
photosensitizer fluorescence (each image is nearly
black) while the viability assessment image contains
bright green nodules, signifying their health. Photobleaching of the photosensitizer can be qualitatively
observed as a decrease in mean pixel intensity when
comparing the pre- and post-treatment PS colormaps
for a PDT treatment in which a fluence of 10 J/cm2
was delivered continuously.

http://www.thno.org
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Figure 1: Imaging-based Quantification of Photosensitizer Uptake, Localization and Photobleaching. Overview of PDT
treatment parameters and the capabilities of the imaging-based approach. The “Change in PS” column denotes pixel-by-pixel subtraction
of post-treatment from pre-treatment photosensitizer fluorescence images. The most intense pixels in these images correspond to the
pixels that were the most photobleached by PDT. Green and red pixels in fluorescence images in the “Imaging Based Viability Assessment”
column denote live and dead characteristics of the nodules, respectively. All data presented here was collected from day 12 AsPC-1
cultures that were allowed to uptake photosensitizer for 4 hours. All scale bars are 350 μm.

http://www.thno.org
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The “Change in PS” colormap is the result of
subtracting the post-treatment image element-wise
from the pre-treatment image and plotted on the same
12-bit colormap. Areas of high photobleaching are
thus visualized here as areas of high pixel intensity.
Though the mathematical basis for this image transformation does not scale pixels to give the percent
photobleaching for each pixel, it is a useful reporter of
the localization of photobleaching in the nodules, and
will heretofore be referred to as the “photobleaching
map.” Finally, dead regions of cells in the viability
assessment can be qualitatively correlated to the high
pixel intensities of the photobleaching map.
These raw fluorescence images and the calculated photobleaching map thus provide rich and
thorough information about PDT parameters. Firstly,
PS fluorescence images collected pre-treatment provide a means to quantify not only mean, but nodule-by-nodule photosensitizer uptake and localization. Pixel intensity line scans (shown as white arrows
in each enlarged nodule images) of single nodules
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reveal the photosensitizer’s localization within the
acini. It can be seen in Figure 1 that photosensitizer is
localized primarily on the outer edges of the nodule
(blue plot, left). From this information, uptake curves
are obtained by imaging selected groups of nodules
that are administered photosensitizer at different uptake times and then taking the mean pixel intensity of
each image (see Figure 2). Similar information is obtained regarding the degree and localization of nodule-by-nodule photobleaching. The plot profile of the
same nodule in the photobleaching map shows that
not only is photosensitizer primarily located on the
periphery of the nodule, but that photobleaching is
highest in the same region (red plot, middle). In the
live and dead fluorescence images under the “Imaging-based Viability Assessment” panel in Figure 1, it
can be seen that the same nodule has nearly no viable
cells in the analogous region where photobleaching
was maximal. Consequently, the most viable cells
survive in the core of the nodule where photobleaching was minimal.
Figure 2: BPD Uptake Curves for
PANC-1 and AsPC-1 3D Cultures.
Method by which photosensitizer uptake
curves are obtained in the 3D model,
beginning with (A) BPD fluorescence
images of day 10 PANC-1 cultures taken
5 minutes after media change to
BPD-free media (images from AsPC-1
cultures not shown for the sake of clarity). Quantified uptake curves were
generated by taking the mean pixel intensities of each image and are presented
for (B) day 12 AsPC-1 and (C) day 10
PANC-1 nodules. Ratiometric increases
in (B) and (C) are reported as the ratio of
the mean pixel intensities of images
collected at 24 hours of uptake to those
collected at 1 hour of uptake. All scale
bars are 350 μm.

http://www.thno.org
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Perhaps the most robust capability of our imaging-based technique is the correlation of photobleaching to treatment response, as shown at the bottom of Figure 1. In particular, the mean residual
photosensitizer (blue bars, bottom graph) can be correlated to mean cytotoxic response (red bars) obtained
from the viability assessment. Using this data, it can
be seen that increasing the light dose results in enhanced cytotoxic response as well as increased mean
photobleaching. Nodule-by-nodule photobleaching
patterns can again be correlated to live and dead patterns seen during treatment evaluation. This is seen in
the bottom right plot profile in Figure 1: the pixel intensity profile for the photobleaching map (black line)
aligns with the live (green line) and dead (red line)
profiles for a selected 10 J/cm2 continuous irradiation
PDT treatment. It should be noted that the observed
alignment at this point is only quasi-quantitative. The
correlation cannot be perfect as the nodule surface
area changes during the 24 hour period in between
treatment and evaluation due to migration of dead
cells from the nodule and continuing growth of viable
cells within the acinus core. The extent of this fluctuation is visible in the bottom right plot profile presented in Figure 1.

Verteporfin Localization and Uptake in 3D
AsPC-1 and PANC-1 Cultures
Figure 2 illustrates how photosensitizer uptake
curves are obtained with our imaging methodology
and how localization can be visualized. Acquired
images from the transmitted light and BPD fluorescence channels from day 10 PANC-1 nodules (Figure
2A) show that no BPD is present in the No Treatment
control, and that both the BPD concentration and localization within the nodules changes with uptake
time. At early uptake durations (1-3 hours), the photosensitizer fluorescence is weak and localized primarily in the outer crust of the nodules. As uptake
time increases, the inner-most cells in the acini gather
more BPD from the cell medium while outer-most
cells reach a relatively constant concentration soon
after exposure to the drug. That is, the uptake time for
the outermost cells is likely more rapid than for those
in the nodule core, whose nutrient transport rates are
limited by the presence of multiple cellular layers
within the nodule. A similar trend is observed in the
AsPC-1 cell line (not shown). Unlike uptake data
taken with these cell lines grown in monolayer, where
uptake is steep up to 4 hours, but then decreases
sharply
[27],
the
BPD
concentration
in
three-dimensional nodules continues to intensify out
to 24 hours of drug uptake.
Using our custom MATLAB routines, the mean
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fluorescence intensity in the raw images was determined, giving a relative estimation of the amount of
photosensitizer in the nodules at each time point. The
resulting uptake curves for day 12 AsPC-1 and day 10
PANC-1 cultures are presented in Figures 2B and 2C,
respectively. The fluorescence intensities of PANC-1
and AsPC-1 cultures are not comparable as different
dynamic ranges were used during imaging. However,
the increase in relative fluorescence intensity between
BPD uptake for 1 hour and 24 hours for the AsPC-1
and PANC-1 cultures was 4.4 and 5.7 fold, respectively. This shows that PANC-1 nodules acquire
photosensitizer faster than AsPC-1 acini, another result that is different from patterns seen in monolayer
data [27].

Optimization of Uptake-dependent PDT
Treatment Parameters
To determine the effect of uptake and localization on treatment response, we conducted continuous
irradiation PDT treatments at 1.5 hour, 4 hour, and 24
hour uptake times for both AsPC-1 and PANC-1 cell
lines. The 4 hour time point was chosen as the uptake
curves in Figure 2 plateau around 4-5 hours while 1.5
hours was chosen as it has been previously studied in
3D cultures [27]. Though 24 hour BPD uptake is not
practical in in vivo models because of BPD’s pharmacokinetics [33], it was nevertheless informative to
examine this upper limit in this mechanistic study.
Figure 3 shows the results of these experiments. It is
readily seen that cytotoxic response is dependent on
uptake time for both cell lines. For AsPC-1 cells, at
lower light doses (i.e., 5 J/cm2), there is a marked enhancement in killing with increasing uptake. However, killing is either worse or unchanged at higher light
doses. PANC-1 cultures show similar behavior,
though killing increases going from 1.5 hours to 4
hours with all light doses.

Optimization of Fractionated Light Delivery
from Photobleaching Patterns
Figure 4 shows the change in treatment response
of 10 J/cm2 delivered continuously and fractionated
(symmetric and asymmetric regimens) with uptake
time in day 12 AsPC-1 cultures. Fractionation schedules are reported as seconds on/seconds off (33/0
denotes continuous irradiation, no rest period). Reported p-values are subscript symbolized as the
comparison between groups with two different dark
intervals for clarity. At only 1.5 hours of verteporfin
uptake, there is no discernable difference between any
fractionation schedule and continuous irradiation.
However, a significant benefit from symmetric fractionation is observed at 4 hours. A two-tailed student
http://www.thno.org
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Figure 3: Uptake Dependent Treatment Response for
PANC-1 and AsPC-1 Cultures (Continuous Irradiation).
Variable treatment response for 5, 10, and 20 J/cm 2 irradiance
delivered continuously with increasing BPD uptake time for (A)
day 12 AsPC-1 and (B) day 10 PANC-1 nodules.

t-test reveals that comparing no dark interval (0s off,
continuous irradiation) to symmetric (33s off) and
asymmetric fractionation (99s off) at 1.5 hours uptake
results in p-values of p0-33=0.572 and p0-99=0.531, respectively. The result of this same comparison at 4
hours uptake is p0-33=0.004 and p0-99<0.001. At 4 hours
uptake, symmetric fractionation (33s on/33s off) does
provide a modest enhancement, and increasingly
asymmetric fractionation (33s on/99s off) provides
even more. To determine why this occurs, we measured the mean photobleaching at 4 hours uptake in
day 12 AsPC-1 cultures for 10 J/cm2 33s/0s and
33s/99s, and then correlated that to mean cytotoxic
response. Figure 4B shows the result of this analysis
and that the enhancement between continuous irradiation and asymmetric fractionation is present and
significant (pV=0.016), but that there is an insignificant
difference between the mean residual BPD in the
wells (pBPD=0.115). From this data, it is clear that, in
comparison to the absence of a dark interval, a statistically significant and greater cytotoxic response is
obtained by fractionating delivered light. However,
the reason for this enhancement cannot be readily
elucidated by using mean field methods to quantify
residual BPD or photobleaching.

Figure 4: Uptake Dependent Treatment Response for
AsPC-1 Cultures (Fractionated Irradiation). (A) Variable
treatment response with uptake time for a constant 10J/cm2 light
dose delivered continuously (33s on/0s off) and with increasing
rest-period asymmetry (33s on/33s off, 33s on/66s off, etc.) for day
12 AsPC-1 nodules. Fractionation schedules are reported as
seconds on/seconds off. Reported p-values are subscript symbolized as the comparison between groups with two different dark
intervals for clarity. (B) Correlation of mean residual BPD to mean
viability in day 12 AsPC-1 nodules with 4 hours of BPD uptake.
Mean residual BPD was normalized to the BPD-only control.

http://www.thno.org
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To determine why fractionation produces a
larger cytotoxic response than continuous irradiation,
we further leverage our imaging based approach to
correlate spatial photobleaching patterns with uptake
and light delivery parameters. Figure 5 summarizes
the data extracted from treatments at 1.5 hours and 4
hours of uptake for day 12 AsPC-1 nodules. Photobleaching maps were generated for the continuous
irradiation and 33s on/99s off regimens for both 1.5
hours and 4 hours of BPD uptake. Pixel intensity line
scans of the photobleaching maps were taken from
nodules that were determined to be of similar diameter along their minor axis (~200 μm) and aspect ratio.
Each line profile presents two peaks on the periphery
of the nodules while the acini cores contain a large dip
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in the pixel intensity. There is little difference in the
distribution of photobleaching comparing only continuous and fractionated light delivery. However, the
thickness of the photobleaching “depth” is dissimilar
comparing 1.5 hours to 4 hours of BPD uptake. The
width of the photobleaching peaks are ~10-40 μm for
1.5 hours uptake while peaks on similarly sized nodules are ~80-100 μm at 4 hours. Referring back to
Figure 1, the depth of photobleaching roughly corresponds to regions of dead cells from the evaluation of
cytotoxic response. This suggests that broader photobleaching peaks correspond to deeper penetration of
cytotoxicity in the acini, as observed from the data in
Figure 5.

Figure 5: Determination of Nodule-by-nodule Photobleaching. Progression from pre- and post-treatment and photobleaching
difference map images to evaluation of the photobleaching pixel intensity profiles of selected nodules (circled in blue) for day 12 AsPC-1
cultures receiving 1.5 hours and 4 hours uptake and 10 J/cm 2 of light delivered (A) continuously or (B) asymmetrically fractionated. All
scale bars are 350 μm.

http://www.thno.org
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Figure 6: Depth of Cytotoxicity for Different Uptake
and Light Delivery Treatments. (A) Inner and outer diameters and (B) calculated depth of cytotoxicity, reported as (outer
diameter – inner diameter)/2, for day 12 AsPC-1 nodules given 1.5
hours and 4 hours of BPD uptake time and treated with 10 J/cm 2
delivered either continuously or asymmetrically fractionated.
Error bars correspond to the standard deviation of the five individual nodules selected per treatment group.

To confirm this assertion, multiple nodules were
selected from each uptake and light delivery group
and the extent by which dead cells protruded into the
nodules was assessed. The “depth of cytotoxicity”
was chosen as a metric instead of “photobleaching
depth” as the viability assessment images were much
cleaner for analysis than the photobleaching maps.
Though there is some dilation in the nodules during
the 24 hour period between PDT treatment and evaluation, it is assumed that most of the change in size is
due to dead cells detaching from the nodules and, as a
result, is systematic across all nodules. Fluorescence
images of the live and dead channels were first binarized. The pixel intensities from the live fluorescence
channel were subtracted element-wise from the dead
channel, resulting in a difference mask consisting of
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the rings of white pixels (corresponding to dead regions) with inner cores (live regions) of black pixels
(not shown). Using ImageJ, multiple line scans were
performed on each of five selected nodules per
treatment group which presented similar outer diameters along their minor axis. The outer and inner diameters along the minor axes of the nodules were
measured and the depth of cytotoxicity defined as the
difference between the outer and inner diameters divided by two.
Figure 6 shows the results of this analysis for
each group that received different BPD uptake time
and irradiation schedules. A student’s t-test analysis
gave that there is no significant difference in the outer
diameters (Figure 6A) of each group of nodules selected for line scan analysis. The inner diameter of the
nodules collected from 4 hour uptake 10 J/cm2
33s/99s group, however, was significantly different
(p=0.003) than the 1.5 hour fractionated group. This
resulted in a significant difference in the depth of cytotoxicity (p=0.040), as presented in Figure 6B. The
average cytotoxic depth of the 4 hour uptake fractionated group was also significantly thicker than in
nodules that received both continuous irradiation
treatments. There was a somewhat significant difference in the cytotoxic depth upon comparing continuous to fractionated light delivery (p=0.018) in the 1.5
hour uptake groups. Finally, there is a very significant
change in cytotoxic depth when comparing continuous irradiation to fractionation with 4 hours of photosensitizer uptake (p=0.003).

Discussion and Conclusion
The unique juxtaposition of high-content quantitative imaging of parameter-dependent spatiotemporal photosensitizer distribution and biologically-relevant tumor models in this study yields several
important insights that may be leveraged for enhanced PDT efficacy. The uptake curves of AsPC-1
and PANC-1 cell lines in these 3D cultures are useful
for the optimization of uptake-dependent PDT treatment parameters, and are the first reported for this
model. Our imaging-based technique shows that the
localization of verteporfin in the nodules changes
with increasing uptake time, quite dramatically
within the first five hours. Given the large depth of
focus in these images, it is probable that the nodule
centers appear brighter than the cells in the periphery
because more fluorescence is integrated from the
thicker nodule cores at long uptake times. That is,
while at certain time points, the cellular BPD concentration is indeed higher in the outermost cells of the
acinus than in the cells constituting the nodule core, it
is highly unlikely that the variation ranges across orhttp://www.thno.org
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ders of magnitude. A future work might involve
careful analysis of frozen sections obtained from a
cyromicrotome thus allowing clearer visualization of
cellular BPD concentrations in the acini cores at longer
uptake times. Nevertheless, the increase in BPD concentration in the cells comprising the acini cores from
1.5 to 4 hours uptake is an especially significant observation as most PDT treatments conducted with this
3D model have utilized only ~1.5 hours of verteporfin
uptake time, though in practice, pharmacokinetic
considerations in vivo would determine the available
window for uptake into the tumor [8]. A limitation of
this model is the absence of any vasculature which, in
vivo, would be a major source of PS delivery. The absence of blood flow in this model could also be particularly limiting when assessing various symmetric
and asymmetric fractionation schemes as reoxygenation times may be longer than diffusion-limited estimates. That is, the vessels may need an extended period of time to reload with oxyhemoglobin when
subjected to heavy photodynamic consumption.
However, extravasation from the vessels and tumor
cell uptake is a diffusion phenomenon, so the above
analysis and methodology remains a useful tool.
The enhanced killing at low light doses with increased uptake time for both cell lines suggests that
fractionation may be more potent in the 3D model at
long uptake times (i.e., ≥4 hours) and with fluences ≤5
J/cm2 per light interval. For low light doses, an uptake
time of 4 hours seems optimal as both cell lines show a
marked plateau in BPD concentration, despite rising
continuously out to 24 hours. Though the 24 hour data
points for both uptake and cytotoxic response were
important for this mechanistic study, the pharmacokinetics of verteporfin do not permit 24 hours of uptake in vivo [33]. While for AsPC-1 cells there was little
dependence on uptake for treatment response at high
light doses, the response of PANC-1 cultures to PDT
treatment departs from AsPC-1 in that killing increases going from 1.5 hours to 4 hours with all light
doses. This is an expected result, however, as Figure 2
shows there is far more photosensitizer in the
PANC-1 nodules at 4 hours than at 1-2 hours of uptake.
Nodule-by-nodule photobleaching can be
roughly correlated to cytotoxic response as shown in
Figure 1. It is difficult to determine quantitatively,
however, the correlation of the most photobleached
regions of the acini to those regions containing the
most dead cells. This is because the photobleaching
maps presented here are derived from images collected directly before and after PDT treatment,
whereas quantitative viability assessments are derived from images taken 24 hours post treatment. At
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this point, many of the dead cells have begun to migrate away from the acini due to PDT disruption of
the nodule structure [9]. The living nodule core has
also had ample time to grow due to continuing mitotic
division of the viable cells. Moreover, the loss of cell
volume regulation in damaged cells can cause more
variation in nodule size 24 hours post-treatment. As a
result, it can be said qualitatively that the areas of
greatest photobleaching are localized on the nodule
crust and that this corresponds to regions of the
greatest death, but the fluorescence intensity distributions for the photobleaching map and dead channels will not line up perfectly with each other as the
nodules’ surface area systematically enlarges during
the 24 hour lag between treatment and evaluation.
This effect can be seen in the line scan profile superposition at the bottom of Figure 1. While this challenge remains to make the approach entirely quantitative, for rapid screening of optimal conditions, it
remains a useful qualitative tool as the extent of the
inner diameter of the nodule in the dead channel (i.e.,
the point in the profile in which the live channel begins to peak) matches fairly well to the corresponding
inner diameter of the photobleaching scan (represented by the region of the nodule with the lowest
degree of photobleaching).
The 4 hour BPD uptake group with fractionated
light delivery had a significantly thicker depth of cytotoxicity than continuous irradiation treatment with
the same uptake (p=0.003) whereas this comparison at
1.5 hours of uptake showed a much smaller (p=0.018),
yet significant difference. This suggests that the depth
of photobleaching is greater upon fractionation when
sufficient BPD is available in the nodules. Fractionation likely does not show a significant benefit in mean
cytotoxicity at 1.5 hours of uptake because of the
scarcity of photosensitizer in the nodule cores. That is,
reoxygenation of the nodule core would likely have
little effect if there is not enough photosensitizer present to utilize it. At 4 hours, as shown by fluorescence
imaging, the cellular BPD concentration is higher in
the nodule core than at 1.5 hours, allowing any reoxygenation intervals to be of use toward achieving superior cytotoxic response.
The small enhancement granted by asymmetric
fractionation is expected when the spatial extent of
nodules in this 3D model is considered. Despite the
presence of hypoxic nodule cores in other 3D models
of this type [28], these acini are not quite large enough
to require extensive reoxygenation as with the vascularized systems previously studied [13]. Theoretical
oxygenation modeling studies with multicellular
spheroids [34] and other in vivo geometries [24, 25]
provide validity to this claim as optimal dark intervals
http://www.thno.org
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for nodules of this size should be ≤5s. Despite these
findings, it is interesting that cytotoxic response is
enhanced with dark intervals as long as 99s; further
exploration of fractionation in the 3D model using a
refined version of our imaging-based technique may
be performed in future work. In addition, though the
enhancement in cytotoxicity between fractionated and
continuous PDT treatment regimens is relatively
modest in this 3D model, the result of unprecedented
seconds-scale asymmetric fractionation merits further
investigation in a model where reoxygenation is more
important (i.e., murine mouse model). As the differences between continuous and symmetric fractionated light delivery were quite dramatic in previous in
vivo studies [13, 25], it is possible that asymmetric
fractionation could provide additional benefit.
In conclusion, the imaging-based approach presented here can be leveraged to visualize and quantify
photosensitizer uptake characteristics, photobleaching patterns, and cytotoxic response to make informed decisions about in vitro PDT treatment parameters. Its utility may also be expanded to aid in
optimization of in vivo PDT treatments of cancer. In
addition, the result of asymmetric fractionation in the
3D model suggests it may have additional benefit in
vivo. Future work with fractionation in the 3D model
and further refinement of our imaging technique may
also lead to greater efficiency and enhancement of
treatment parameters in both fractionated and continuous irradiation schemes. Finally, though not
studied here, the effects of increased photosensitizer
dose administered to the nodules could also be determined using the imaging-based technique, leaving
even more potential for further characterization and
implementation of the method.
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